Autolus Therapeutics plc (AUTL)

Etorro trading 970x250
Autolus Therapeutics plc (AUTL) Logo

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. Address: Forest House, London, United Kingdom, W12 7RZ

Autolus Therapeutics plc News and around…

Latest news about Autolus Therapeutics plc (AUTL) common stock and company :

What Is The Ownership Structure Like For Autolus Therapeutics plc (NASDAQ:AUTL)?
03 Dec, 2021 Yahoo! Finance

The big shareholder groups in Autolus Therapeutics plc ( NASDAQ:AUTL ) have power over the company. Institutions often...

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
15 Nov, 2021 Yahoo! Finance

LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. William D. Young, a Senior Advisor to Blackstone Life Sciences, has been appointed as a non-executive director to its board of directors, effective immediately. The appointment is pursuant to the recently announced investment from Blackstone Life Sciences. Dr. Young will serve as a Class III

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
10 Nov, 2021 Yahoo! Finance

Tetracycline and minocycline controllable CAR T cell system to manage toxicitiesLONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of an article in Nature Scientific Reports describing a controllable CAR T cell system (TetCAR), designed to reversibly dampen the activity of the programmed T cells by the administration of the licensed an

64 Biggest Movers From Yesterday
09 Nov, 2021 FinancialContent

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced ...

Why Autolus Therapeutics Stock Jumped 25% Today
09 Nov, 2021 FinancialContent

A private equity firm is taking a $100 million stake in the biotech.

Mid-Afternoon Market Update: eHealth Drops Following Q3 Results; Autolus Therapeutics Shares Gain
08 Nov, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 0.12% to 36,372.57 while the NASDAQ rose 0.23% to 16,009.02. The S&P also rose, ...

Mid-Day Market Update: Trade Desk Jumps After Upbeat Results; GT Biopharma Shares Slide
08 Nov, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.34% to 36,452.79 while the NASDAQ rose 0.18% to 16,000.97. The S&P also rose, ...

38 Stocks Moving In Monday's Mid-Day Session
08 Nov, 2021 FinancialContent

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its ...

12 Health Care Stocks Moving In Monday's Intraday Session
08 Nov, 2021 FinancialContent

Gainers PetVivo Holdings (NASDAQ:PETV) shares increased by 27.75% to $4.51 during Monday's regular session. As of 11:30 EST, this ...

DSAC Stock Pops on FiscalNote SPAC Merger News. 14 Things to Know.
08 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Duddell Street Acquisition (DSAC) stock is on the move Monday following news of a special purpose acquisition company merger with FiscalNote. The post DSAC Stock Pops on FiscalNote SPAC Merger News. 14 Things to Know. appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Chinese Stocks Alert: The Turnaround Story Driving TAL, EDU, METX, GOTU Stocks Higher
08 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chinese education stocks are moving higher on Monday as reports claim China will allow companies to resume their after-school tutoring. The post Chinese Stocks Alert: The Turnaround Story Driving TAL, EDU, METX, GOTU Stocks Higher appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Blackstone to Invest $250M in Autolus Therapeutics
08 Nov, 2021 Yahoo! Finance

By Sam Boughedda

AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Higher Today
08 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Autolus Therapeutics (AUTL) stock is surging higher in trading Monday following news of a major investment in the company. The post AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Higher Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Mid-Morning Market Update: Markets Rise; Coty Posts Upbeat Earnings
08 Nov, 2021 FinancialContent

Following the market opening Monday, the Dow traded up 0.40% to 36,472.70 while the NASDAQ rose 0.20% to 16,003.39. The S&P also ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
08 Nov, 2021 FinancialContent

Gainers Autolus Therapeutics (NASDAQ:AUTL) stock rose 21.04% to $6.73 during Monday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
08 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We're starting off the week strong with a dive into the biggest pre-market stock movers for Monday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

26 Stocks Moving in Monday's Pre-Market Session
08 Nov, 2021 FinancialContent

Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science ...

Autolus Stock Rallies On $250M Investment From Blackstone
08 Nov, 2021 FinancialContent

Blackstone Inc(NYSE: BX)will invest $250 millioninAutolus Therapeutics plc(NASDAQ: AUTL) to fund the ...

Autolus Jumps; Blackstone Invests Up to $250M in Leukemia Therapy
08 Nov, 2021 Yahoo! Finance

Obe-Cel Autolus's next generation leukemia treatment candidate. Blackstone is backing the company with up to $250 million.

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
08 Nov, 2021 Yahoo! Finance

– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of obe-cel supports its potential as the first stand-alone therapy in adult ALL with curative potential in a last line setting – Blackstone strategic financing to enable Autolus to complete clinical development of obe-cel in its first indication of relapsed / refractory adult ALL and to support initial p

Blackstone to invest up to $250 million in British biotech company Autolus
08 Nov, 2021 FinancialContent

Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said.

Blackstone to Invest Up to $250 Million in Autolus Therapeutics of U.K.
08 Nov, 2021 Yahoo! Finance

The funds will help develop a leukemia therapy. Under deal, the private-equity firm intends to buy a $100 million stake in the biotech company.

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
04 Nov, 2021 Yahoo! Finance

- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14, 2021 at 8:00 am ET / 1:00 pm GMT LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an oral presentation related to the industrialization of its manufacturi

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
03 Nov, 2021 Yahoo! Finance

Conference call to be held on November 3, 2021, at 8:30 am ET/12:30 pm GMTLONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2021. “We continue to make good progress on the clinical evaluation of obe-cel in the Phase 2 portion of the FELIX study and remain on track to deli

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3
25 Oct, 2021 Yahoo! Finance

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021. Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business up

Analysts Expect BIB To Hit $114
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.26 per unit.

Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well
08 Oct, 2021 FinancialContent

The FDA has sent shockwaves through the off-the-shelf CAR-T space after itslapped a clinical holdon all of theAllogene ...

Autolus Therapeutics (NASDAQ:AUTL) shareholders have endured a 76% loss from investing in the stock three years ago
04 Oct, 2021 Yahoo! Finance

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the...

Autolus Therapeutics Breaks Above 200-Day Moving Average - Bullish for AUTL
27 Sep, 2021 FinancialContent

In trading on Monday, shares of Autolus Therapeutics PLC (AUTL) crossed above their 200 day moving average of $6.80, changing hands as high as $6.88 per share. Autolus Therapeutics PLC shares are currently trading up about 8.1% on the day..

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
16 Sep, 2021 FinancialContent

- Allowing global commercial launch capacity for obe-cel (AUTO1)

Autolus Therapeutics plc (AUTL) is a NASDAQ Common Stock listed in , ,

970x250